NO INVESTMENT ADVICE The content on this Site is provided for information purposes only and does not constitute investment advice, a personal recommendation, an offer or solicitation to buy or sell securities, or any other regulated activity. It should not be relied upon as the basis for any investment decision. Before making any investment decision, you should: Read the relevant prospectus, term sheet, subscription agreement, or other offering documentation in full Consider whether the investment is suit ...

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*.VINIA's leadership position is driven by its clinically demonstrated ability to increase arterial dilation, improving bl ...

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on ...

Core Viewpoint - BioHarvest Sciences Inc. has approved long-term incentive awards to align employee interests with shareholder value and support growth across its business segments [1][3]. Group 1: Long-term Incentive Awards - The awards include 516,812 stock options and 264,121 restricted share units (RSUs), with stock options valid for 10 years and both options and RSUs vesting quarterly over three years starting March 13, 2026 [2]. - The equity-based incentives are designed to reward and retain top talent while minimizing immediate cash impact on the company [3]. Group 2: Business Strategy and Growth - BioHarvest is focused on expanding its proprietary Botanical Synthesis platform in consumer nutraceutical products and its contract development and manufacturing organization (CDMO) division [4]. - The company emphasizes the importance of attracting and retaining exceptional talent as a key driver of sustainable growth and shareholder returns [4]. Group 3: Company Overview - BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without growing the underlying plants [5]. - The company aims to develop science-based therapeutic solutions in two major business verticals: as a CDMO and as a creator of proprietary nutraceutical health products [5].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - BioHarvest Sciences Inc. announces the resignation of Mr. David Tsur from its Board of Directors after over four years, and the appointment of Prof. Hezi Levy to the Board, effective immediately [1][2]. Group 1: Board Changes - Mr. David Tsur has been a member of BioHarvest's Board since 2021, contributing significantly to the company's strategic development during a period of operational expansion and product commercialization [2]. - Chairman Zaki Rakib expressed gratitude for Mr. Tsur's leadership and contributions, highlighting his role in supporting the company's growth and strategic evolution [3]. - Prof. Hezi Levy brings decades of leadership experience in Israel's healthcare system, having previously served as Director General of the Israeli Ministry of Health and played a key role during the COVID-19 pandemic [3][4]. Group 2: Prof. Hezi Levy's Background - Prof. Levy has extensive experience, including serving as Head of the Medical Corps of the Israel Defense Forces (IDF) and General Manager of Barzilai Medical Center, overseeing major healthcare operations [4]. - His medical expertise and executive leadership are expected to strengthen BioHarvest's governance as the company scales its direct-to-consumer products and advances its biotechnology CDMO platform [5]. Group 3: Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing patented technology to grow plant-based compounds without the need for the underlying plants [5]. - The company focuses on developing science-based therapeutic solutions in two main areas: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].

Core Insights - BioHarvest Sciences Inc. has been invited to the 38th Annual Roth Conference, providing a platform to showcase its business to sophisticated investors [1][2] - The company is at a significant inflection point following a successful Q4 2025 financing round, which has fully funded its near-term capital expenditures [2] - BioHarvest has over 85,000 direct customers and is focused on accelerating growth in its Contract Development and Manufacturing Organization (CDMO) and Consumer Product businesses [2] Company Overview - BioHarvest Sciences Inc. specializes in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need for growing the actual plants [3] - The company operates in two main business verticals: as a CDMO for clients seeking novel plant-based compounds and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [3]

Group 1 - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment [1] - The article suggests that investors should consider buying TEM stock based on analysts' recommendations [1]

Core Insights - Riverwater Partners' Small Cap Strategy underperformed the Russell 2000 Index in Q4 2025 and for the entire fiscal year 2025, primarily due to stock selection and an emphasis on high-quality stocks that lagged behind broader market trends [1] - The firm anticipates a more favorable environment for high-quality businesses in 2026 [1] Company Highlights - BioHarvest Sciences Inc. (NASDAQ:BHST) is a biotechnology company focused on developing technology for higher concentrations of active ingredients from plant cells [2] - Over the past 52 weeks, BioHarvest Sciences Inc. shares traded between $4.72 and $12.80, closing at $5.77 on January 22, 2026, with a one-month return of 8.26% but a three-month loss of 49.87% [2] - The market capitalization of BioHarvest Sciences Inc. is approximately $130.788 million [2] Investment Strategy - Riverwater Partners initiated a position in BioHarvest Sciences Inc. during Q4 2025, having monitored the company for about 18 months and engaged in multiple meetings with its CEO [3] - The firm participated in a recent secondary offering of BioHarvest Sciences Inc. at a discount to its trading valuation, highlighting the attractiveness of its Botanical Synthesis platform for sustainable production of plant phytochemicals [3] - BioHarvest Sciences Inc. currently generates revenue from its VINIA nutraceuticals franchise, which utilizes resveratrol from grapes for health benefits, and the firm plans to increase its position over the next 6–12 months as the company executes its growth plan [3]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]